Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

rilimogene galvacirepvec

A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	PROSTVAC-V PROSTVAC-V/TRICOM recombinant vaccinia-PSA(L155)/TRICOM vaccine rvaccinia-prostate-specific antigen-TRICOM vaccine rvaccinia-PSA-TRICOM vaccine
Abbreviation:	vPSA-TRI

rilimogene galvacirepvec

Search NCI's Drug Dictionary